Abeona Therapeutics Inc. (NASDAQ:ABEO) Q2 2019 Earnings Conference Call - Final Transcript

Aug 12, 2019 • 10:00 am ET


Abeona Therapeutics Inc. (NASDAQ:ABEO) Q2 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good morning, ladies and gentlemen, and welcome to the Abeona Therapeutics Inc. Second Quarter 2019 Earnings and Business Update Conference Call. Today's call is being recorded. And at this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. For opening remarks and introductions, I'll turn the call over to Sofia Warner, Senior Director, Investor Relations. Thank you. You may begin.

Sofia Warner

Thank you. Good morning, and welcome, everyone. Today's call will be led by Joao Siffert, our Chief Executive Officer. Following Joao, Tim Miller, our President and Chief Scientific Officer, will present preclinical highlights; and Christine Silverstein, our Chief Financial Officer, will review our financials. Before I turn the call over to them, I need to remind our listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in these statements is based on current expectations and is subject to change, and actual results may differ materially from forward-looking statements. Some of the factors that could cause actual results to differ may be found in the company's annual report on Form 10-K and quarterly report on Form 10-Q to filed by the company with the Securities and Exchange Commission. These documents are available on our website www.abeonatherapeutics.com.

With that said, it is now my pleasure to introduce to you, Dr. Joao Siffert. Joao, you have the floor.

Joao Siffert

Thank you, Sofia, and thank you all for joining us today for our second quarter results and business highlights, which we believe reflects substantial progress in the continued development of our clinical and preclinical programs, as well as our manufacturing and quality operations. Today, I'll review the key quarter accomplishments and recent events and then turn the call over to Tim, who will discuss the developments within our preclinical programs and updates from our next-generation AIM capsid platform.

I'd like to start off with an update on our recessive dystrophic epidermolysis bullosa program. As a reminder, RDEB is a rare and severely debilitating genetic skin disorder caused by mutations, which result in lack of functional Collagen VII, the main component of the anchoring fibrils that attach the dermis to the epidermis. Without functional Collagen VII, RDEB patients have extremely fragile skin, the blisters and tears, ultimately leading to multiple wounds, some of which remain open for years and cover a significant amount of the body. RDEB wounds are very painful lead to multiple dermatological and sustained complications and currently have no effective treatment options.

Patients rely on palliative treatments that include time-consuming and expensive wound care to protect open wounds, reduce pain, prevent infection and often require comprehensive pain management. We're currently developing EB-101, autologous, gene-corrected cell therapy that restores normal functional Collagen VII to keratinocytes and their progenitors. Each EB-101 gene-corrected keratinocyte sheet, which can cover an area of approximately 35 to 40 centimeter squared, is transplanted into open wounds